Influence of psychiatric diagnosis on treatment uptake and interferon side effects in patients with hepatitis C
| Autor: | Bruce Shadbolt, Shivakumar Chitturi, Geoff Farrell, Anne Blunn, Ilys Rodriguez-Morales, Caroline To, Narci C. Teoh, Kalyana Rodrigo, Jing Yuan J Wu, Graham Kaye |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
medicine.medical_specialty
Hepatology business.industry Ribavirin education.educational_degree Gastroenterology Psychiatric rehabilitation Hepatitis C Odds ratio medicine.disease chemistry.chemical_compound chemistry Schizophrenia Internal medicine medicine History of depression Liaison psychiatry education business Psychiatry Depression (differential diagnoses) |
| Zdroj: | Journal of Gastroenterology and Hepatology. 29:1258-1264 |
| ISSN: | 0815-9319 |
| DOI: | 10.1111/jgh.12515 |
| Popis: | Background and Aim Pegylated-interferon-α/ribavirin (PEG-IFN/RBV) treatment can cure hepatitis C virus (HCV) infection but has frequent neuropsychiatric side-effects. Patients with pre-existing psychiatric illness may not be offered therapy. We established prevalence of self-reported psychiatric comorbidity among HCV-infected patients in a hospital-liver clinic, and determined the impact of such diagnoses on uptake and tolerance to PEG-IFN/RBV. Methods All HCV cases referred for assessment in Australian Capital Territory/surrounding regions April 2004–March 2012 were entered into a clinical database. We conducted univariate and multivariate analyses of variables correlating with uptake of antiviral therapy and frequency of treatment-related side-effects. Results Of 773 referred patients, 235 (30%) described pre-existing psychiatric illness. Among these, 26% received antiviral therapy, compared with 30% of 538 without psychiatric comorbidity. History of depression (usually validated by liaison psychiatry) was associated with higher incidence of treatment-related neuropsychiatric side-effects (odds ratio 2.79 [1.35–5.70], P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text